Stockscreener 앱 받기
7.02
1.40%
-0.10
시간 외 거래:
7.04
0.02
+0.28%
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - MarketBeat
Geopolitics Watch: Is DiaMedica Therapeutics Inc. stock attractive for ETFsQuarterly Profit Review & Daily Profit Focused Screening - Naître et grandir
DiaMedica Therapeutics raises capital via share offering - MSN
DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33 - Defense World
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV) - The Globe and Mail
DiaMedica receives Health Canada clearance for preeclampsia study By Investing.com - Investing.com South Africa
Sentiment Watch: Whats the fair value of AEV CL stockAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
DiaMedica Therapeutics receives Health Canada clearance to initiate phase 2 study of DM199 in preeclampsia - marketscreener.com
Corient IA LLC Acquires New Holdings in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Risk Analysis: Can DiaMedica Therapeutics Inc lead its sector in growthPortfolio Value Summary & Fast Momentum Entry Tips - baoquankhu1.vn
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.1%Time to Sell? - MarketBeat
Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Yahoo Finance
Rate Cut: Is DiaMedica Therapeutics Inc stock a top performer YTDJuly 2025 Price Swings & Daily Market Momentum Tracking - baoquankhu1.vn
Earnings Recap: Can DiaMedica Therapeutics Inc keep up with sector leadersGold Moves & Consistent Profit Trading Strategies - baoquankhu1.vn
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
DMAC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Recap: How does DiaMedica Therapeutics Inc compare to its peersJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
How DiaMedica Therapeutics Inc. stock trades before earningsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - mfd.ru
Fichthorn reports 0.3% DiaMedica (DMAC) stake as Dialectic entities exit - Stock Titan
Trading Recap: Is FURY a play on infrastructure spendingWeekly Market Outlook & Community Trade Idea Sharing - baoquankhu1.vn
DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their Holdings - Yahoo Finance
Is DiaMedica Therapeutics Inc a cyclical or defensive stockAnalyst Downgrade & Technical Confirmation Trade Alerts - baoquankhu1.vn
DMAC Technical Analysis & Stock Price Forecast - Intellectia AI
Swing Trade: Can DiaMedica Therapeutics Inc keep up with sector leadersTrade Signal Summary & Community Supported Trade Ideas - baoquankhu1.vn
Is DiaMedica Therapeutics Inc. stock a top performer YTDJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Highs Report: How does DiaMedica Therapeutics Inc compare to its peersChart Signals & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Strengthens Balance Sheet With $12.2 Million Capital Raise While Advancing Preeclampsia Program - Longbridge
Dividend Watch: Can DiaMedica Therapeutics Inc. keep up with sector leaders2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Insiders continue to buy DiaMedica Therapeutics Inc. (NASDAQ:DMAC) and now own 47% shares - simplywall.st
Cantor Fitzgerald Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock - Investing.com
Aug Final Week: Whats next for CWAN stockJuly 2025 Update & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
What technical charts say about DiaMedica Therapeutics Inc. stock2025 Volume Leaders & Free Expert Approved Momentum Trade Ideas - bollywoodhelpline.com
Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8% - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The AI Journal
Trading Action: Why DiaMedica Therapeutics Inc. stock is a value investor pickWeekly Profit Analysis & Low Risk Entry Point Tips - Bộ Nội Vụ
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Panic Selling: Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - Улправда
DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.3%Should You Sell? - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):